AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01581476 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Combination therapy
Description: Participants receive both active statin and active ACEI. Dose for Statins is 10mg daily. Dosing for ACEI starts at 5mg daily rising to 10mg after 14 days providing it is well tolerated. Both interventions last for a minimum of 2 years.
Study NCT01326624 — intervention group
Intervention type: DEVICE
Intervention: wearable defibrillator (LifeVest)
Description: LifeVest wearable defibrillator for unattended treatment of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation
Study NCT03767959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chen's U-Suture
Description: Chen's U-Suture is a new technique of the invaginated end-to-end pancreaticojejunostomy with transpancreatic transverse U-sutures
Study NCT03767959 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic pancreatic duct to mucosa
Description: A Classical anastomosis technique for Pancreaticojejunostomy
Study NCT04683055 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification combined with trabeculectomy
Description: Patients with chronic angle closure glaucoma assigned to this group will have fornex based trabeculectomy at superior limbus and then phacoemulsification via temporal incision
Study NCT04683055 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsificaiton combined with ab-externo trabeculotomy
Description: Patients with chronic angle closure glaucoma assigned to this group will have Deep Sclerectomy with ab externo trabeculotomy at superior limbus and then phacoemulsification via temporal incision
Study NCT03495908 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VGo
Description: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.
Study NCT03495908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VGo
Description: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.
Study NCT01595620 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Thermal
Description: Thermal sensation/pain testing
Study NCT01595620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thermal
Description: Thermal sensation/pain testing
Study NCT01595620 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electrical
Description: Electrical sensation/pain testing
Study NCT01595620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrical
Description: Electrical sensation/pain testing
Study NCT01595620 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin
Description: Intradermal Capsaicin
Study NCT01595620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Description: Intradermal Capsaicin
Study NCT00870714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole 400mg P.O. BID daily to start on day 2 following the first docetaxel treatment. In patients who experience no grade 2 or higher toxicity, the ketoconazole dose will be increased to 400mg TID on day 2 following cycle #2 of docetaxel. This will be continued daily until completion of study treatment.
Study NCT01595620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: Active THC (0.01 mg/kg) administered over 10 minutes
Study NCT02440919 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyperoxygenation 100% FiO2
Description: Endotracheal suction associated with Hyperoxygenation involved supplying 100% oxygen.
Study NCT02440919 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyperoxygenation 20% FiO2
Description: Endotracheal suction associated with Hyperoxygenation involved supplying 20% oxygen above FiO2 basal.
Study NCT01595620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: Active THC (0.03 mg/kg) administered over 10 minutes
Study NCT01595620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: small amount of alcohol with no THC, administered over 10 minutes
Study NCT03767491 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Smartphone-delivered CBT for OCD
Description: 12-week Smartphone-delivered CBT for OCD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for OCD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
Study NCT03767491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered CBT for OCD
Description: 12-week Smartphone-delivered CBT for OCD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for OCD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
Study NCT03753958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: The treatment will consist of oral hygiene orientation, with brushing technique instructions and daily flossing recommendation. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with an ultrasound equipment and curettes for root scaling and straightening13. In implants, calculus will be removed with specific curettes for use on the implant surface. Treatment will be performed in 2 to 4 sessions under local anesthesia. Other biofilm-retaining factors, such as carious lesions, condemned teeth and maladaptive restorations, will be removed during these periodontal treatment sessions.
Study NCT03753958 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: aPDT
Description: aPDT will be performed after conventional treatment, in sites with pockets greater than or equal to 5 mm. The PapaMblue® photosensitizer with 100 μM methylene blue will be deposited in the pockets with a syringe, with the bottom of the pouch in the coronal direction, and a pre-irradiation time of 1 min will be adopted, so that the PS may stain the entire bacterial biofilm. Then, the laser emitting an wavelength of 660 nm, with power of 100 mW, will be applied. The laser will be applied to the mucosa on the oral epithelium with an optical fiber (apparatus of DMC Therapy EC, São Carlos, Brazil). Irradiation will be performed until the entire peri-implanted pouch is illuminated for 2 minutes at each point. The 6 points around the implant will be irradiated and each irradiation point will present an area of 0.4 cm2, which will result in radiant exposure of 30 J/cm2 following 2 min of irradiation per point. The irradiation will have a constant power density of 250 mW/cm2.
Study NCT02334748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab
Description: canakinumab
Study NCT02573987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen/nitrous oxide equimolar mix
Description: an experimental strategy inhalation by means of a breathing mask diffusing MEOPA
Study NCT02871466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stem cells infusion
Study NCT02573987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: standard strategy by local injection anesthesia of lidocaine
Study NCT01840592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Study NCT01840592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT01177501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Six sequential doses established in the absence of limiting toxicity, as follows : 7.5 - 8.0 - 8.5 - 9.0 - 10.0 mg/m²
Study NCT03246009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHSA/GCSF
Description: single injection-1.8mg
Study NCT03246009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHSA/GCSF
Description: single injection-2.1mg
Study NCT04762771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine dosing = 0.6 mg bid x 30 days Decrease dose to 0.3-0.6 mg daily or every other day in setting of gastrointestinal intolerance (nausea, diarrhea, emesis, abdominal discomfort) Decrease dose to 0.6 mg daily in the setting of weak or moderate CYP3A4 inhibitor Decrease dose to 0.3 mg daily in the setting of strong CYP3A4, P-glycoprotein inhibitors, or protease inhibitors Decrease dose to 0.3 mg daily in the setting of chronic kidney disease (CKD) stage ≥ 4 (CrCl ≤ 30 ml/min) or liver failure (aspartate aminotransferase /alanine aminotransferase > 3x normal).~Decrease dose to 0.6 mg every 14 days in patients with end stage renal disease (ESRD) or requiring dialysis Route of Administration: oral
Study NCT03246009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHSA/GCSF
Description: single injection-2.4mg
Study NCT03246009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHSA/GCSF
Description: multiple injection-1.8mg
Study NCT03246009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHSA/GCSF
Description: multiple injection-2.1mg
Study NCT03359473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2881078
Description: GSK2881078 will be available as capsules for oral administration. GSK2881078 will be administered once daily by the oral route at a dose of 1 mg and 2mg to post-menopausal female subjects and male subjects, respectively.
Study NCT03359473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Subjects will be administered two capsules of GSK2881078 matching placebo once daily by the oral route.
Study NCT03246009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHSA/GCSF
Description: multiple injection-2.4mg
Study NCT00984841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored letter
Study NCT00984841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tailored letter
Study NCT04616144 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fresh Corneal Lenticule Implantation using Relex-Smile VisuMax Femtosecond Laser
Description: Fresh Corneal Lenticule Implantation using ReLex-Smile
Study NCT02918318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
Study NCT02918318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal esketamine (28 mg)
Description: Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
Study NCT02918318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal esketamine (56 mg)
Description: Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
Study NCT02918318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal esketamine (84 mg)
Description: Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
Study NCT03493945 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1,200 mg IV once every 2 weeks
Study NCT03493945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: 8-15 mcg/kg subcutaneous every 2 weeks
Study NCT02440919 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyperinflation (PEEP- ZEEP) Basal FiO2
Description: Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and involved no hyperoxygenation, keeping the oxygen already offered to the patient.
Study NCT02440919 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyperinflation (PEEP- ZEEP) 20% FiO2
Description: Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and hyperoxygenation involved supplying 20% oxygen.
Study NCT03493945 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Brachyury
Description: MVA-BN-Brachyury will be administered subcutaneously (2 doses 2 weeks apart).
Study NCT03493945 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FPV-Brachyury
Description: FPV-Brachyury will be given 2 weeks after second dose of MVA-BN-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 month.
Study NCT00780572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADE alert assistant
Description: A note in CPRS alerting providers that patients are at risk for an adverse event based on prescription and lab value histories.
Study NCT02749903 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: enzalutamide
Description: oral
Study NCT02181231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: venlafaxine XR
Description: slow titration up to maximum dose of 300mg per day, will remain on venlafaxine XR for up to 32 weeks
Study NCT02181231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine XR
Description: slow titration up to maximum dose of 300mg per day, will remain on venlafaxine XR for up to 32 weeks
Study NCT02181231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: randomized to either buprenorphine or placebo, dose range from 0.2 mg/ qd to 2mg/ qd
Study NCT02181231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will remain on venlafaxine XR and be randomized to receive either placebo or buprenorphine for 8 weeks. at the end of the 8 weeks those who did not receive buprenorphine will be offered the opportunity to try it.
Study NCT03372408 — intervention group
Intervention type: OTHER
Intervention: Chart review
Description: Retrospective chart review of program participation and socio-demographic \& psychosocial characteristics
Study NCT02422381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: Investigational drug.
Study NCT02422381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard care drug.
Study NCT01711086 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerolizer Followed by Inspiromatic
Description: Participants will receive Formoterol (Foradil) 12mcg via the Foradil Aerolizer inhaler while performing lung function as part of the and not differ from other routine follow-up
Study NCT01711086 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiromatic followed by Aerolizer
Description: Participants will receive Formoterol (Foradil) 12mcg via the Inspiromatic dry powder inhaler while performing lung function instead of getting it via the Foradil Aerolizer
Study NCT02144675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: choline magnesium trisalicylate
Description: Given PO
Study NCT02144675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study NCT02144675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: idarubicin
Description: Given IV
Study NCT02144675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT02144675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: Given IV
Study NCT02144675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02144675 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01813019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Description: mGluR5 antagonist
Study NCT01813019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT04003597 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual-salt diet
Description: Subjects followed their usual-salt diet but were asked to consume an equivalent in-house produced brown or white sliced pan bread equivalent in composition to the low-salt version but with its more typical salt content (1.2 g/100 g).
Study NCT04003597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reduced-salt diet
Description: Subjects randomized to start on the reduced-salt diet were asked to restrict their consumption of dietary salt using a combination of pragmatic dietary advice as well as the replacement of bread and a limited number of other foods with equivalent foods which had lower salt content; these were provided to the participants. At the beginning of the salt restriction period, a research nutritionist provided the subjects with a list of the common salt-containing food (salted and naturally salty) and were asked to limit the consumption of such, as feasible. The subjects received in-house prepared 'low-salt (\<0.3 g/100 g)' brown or white sliced pan bread as well as no-salt margarine/butter, and were given luncheon meats with no added salt if desired (optional).
Study NCT03737461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogenic BM-MSCs Injection
Description: Cell dose will be 20±5 million cells suspended in 2 ml of HypoThermosol isotonic transport solution
Study NCT03737461 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: sham-maneuver as in the cell-treated patients are added, consisting in anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment.
Study NCT03074734 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exposure to secondhand tobacco smoke
Description: The intervention is exposure to secondhand smoke of COPD and asthma patients in outside smoking areas (no specific drugs or devices are tested in this study). Study subjects will be asked to spend at least 15 minutes in the outdoor smoking area, a preferable time of 30-60 mins. During the exposure period (15-60 min) subjects´ respiratory rates will be recorded using RESpeck device, as well as the air quality which will be monitored using AirSpeck device.
Study NCT04694833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor and cognitive virtual reality-based assessments
Description: Motor and cognitive testing in virtual reality
Study NCT04694833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor and cognitive virtual reality-based serious games
Description: Serious games implemented in virtual reality to rehabilitate motor and cognitive impairments.
Study NCT00374777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem MR
Description: oral
Study NCT00374777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitrazepam
Description: oral
Study NCT00374777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study NCT06410105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLEAR ALIGNERS
Description: The CA group included 13 patients treated with clear aligners Tree-dimensional images were captured using a CBCT scan (KaVo® Dental GmbH, Bismarckring, Germany). Te pre-treatment imaging parameters were 120 kV, 5 mA, 0.3 mm voxel size, and a feld of view of 230×170 mm
Study NCT03675659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intra-articular injection
Description: intra-articular injection with magnesium sulfate with four injections at weekly intervals
Study NCT03675659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-articular injection
Description: intra-articular injection with magnesium sulfate with four injections at weekly intervals
Study NCT01391117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo.
Description: panel 1: 2 participants receive placebo at a q24h regimen.
Study NCT01391117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo.
Description: panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
Study NCT01391117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC649128.
Description: panel 2, arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
Study NCT01391117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo.
Description: panel 2, arm 2: 2 participants receive placebo at a q24h regimen.
Study NCT01391117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: panel 4, arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
Study NCT01391117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC649128
Description: panel 4, arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
Study NCT01391117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC649128.
Description: panel 2, arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
Study NCT01391117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC649128
Description: panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.